On the Couch with Dr Leslie Chong CEO Imugene (IMU) August 2022

Transcript - TBC   Welcome to another episode of On the Couch with Henry Jennings. Henry is talking to Dr Leslie Chong, CEO and MD of Imugene (IMU). Imugene is a very interesting look at an early stage biotech, where it is with trials and data, plus some words of advice on how to look at investing in biotech's in general. And a quick chat on Italian art to finish off. A great podcast and well worth a listen. Leslie has 24 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in two marketed oncology products. She was previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.   More about the author – Henry Jennings Henry Jennings, Senior Market Analyst and Media Commentator at Marcus Today Stock Market Newsletter, has been involved in financial markets since the 80s in London before emigrating to Australia. He first joined Deutsche Bank and then Macquarie Bank as Head of Equity Trading in Sydney. Since leaving Macquarie, Henry has been both an institutional and private client adviser. For the last seven years, Henry has been writing strategy and insights daily and is a frequent media commentator on all things finance on ABC TV and Radio, SBS and Ausbiz. He also hosts a series of podcasts talking to industry experts and the popular live Ask the Analyst session for Marcus Today.

Get access to more market commentary, sign up for a free trial now and become a better investor.